Achieving protection against HBV in HIV patients: Finding the best strategy.
HBV and HIV coinfection is common and entails important morbi-mortality. Vaccination and anti-HBs seroconvertion is a desirable goal in HIV infected patients. New strategies are necessary to predict seroconversion and clinical endpoints. More studies, in the subgroup of HIV patients with poor immunovirological status are needed.
a Gastroenterology Department, School of Medicine , Pontificia Universidad Catolica de Chile , Santiago , Chile.|b Hepatology Unit , Hospital Gustavo Fricke , Viña del Mar , Chile.
Jose Ignacio
JI
Vargas
a Gastroenterology Department, School of Medicine , Pontificia Universidad Catolica de Chile , Santiago , Chile.|c Division of Gastroenterology and Hepatology , Mayo Clinic , Rochester , MN , USA.
Juan Pablo
JP
Arab
d Endocrinology Department , School of Medicine, Pontificia Universidad Católica de Chile , Santiago , Chile.
Daniela
D
Jensen
b Hepatology Unit , Hospital Gustavo Fricke , Viña del Mar , Chile.
Francisco
F
Fuster
D015658:HIV Infections / Q000150:complications* / Q000276:immunology*; D006509:Hepatitis B / Q000517:prevention & control*; D006801:Humans; D007115:Immunization Schedule
HBV; HIV; hepatitis; immunization; vaccine
J Med Virol. 2016 Apr;88(4):639-46
26381185
Vaccine. 2016 Apr 7;34(16):1889-95
26945101
Vaccine. 2011 May 23;29(23):3977-81
21473954
HIV Med. 2016 Feb;17 (2):83-8
26548563
Hepatology. 2009 May;49(5 Suppl):S138-45
19399813
Lancet. 2002 Dec 14;360(9349):1921-6
12493258
Hum Vaccin Immunother. 2015;11(1):263-9
25483544
HIV Med. 2013 Nov;14 Suppl 4:1-71
24581304
J Infect Dis. 2016 Jul 1;214(1):16-22
26802139
MMWR Suppl. 2013 Feb 1;62(1):1
23364301
PLoS One. 2013 Nov 12;8(11):e80409
24265819
JAMA Intern Med. 2016 May 1;176(5):603-10
27064975
Lancet Infect Dis. 2012 Dec;12(12):966-76
23174382
JAMA. 2011 Apr 13;305(14):1432-40
21486976
J Infect Dis. 2012 Jan 15;205(2):185-93
22147794
Lancet Infect Dis. 2015 Nov;15(11):1283-91
26257021
AIDS. 2005 Mar 24;19(6):593-601
15802978